Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
CRA names Patrick Hillan vice president, expanding Life Sciences commercial strategy expertise
“I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical...